CurrentUnitedHealthcarePolicy 2026T0101NN

Vagus and External Trigeminal Nerve Stimulation – Commercial and Individual Exchange Medical Policyopen_in_new

Defines UnitedHealthcare Commercial and Individual Exchange coverage rationale, clinical criteria, and coding references for implantable vagus nerve stimulators, and states noncoverage for implantable VNS for indications beyond epilepsy and for transcutaneous/non-implantable VNS and external trigeminal nerve stimulation for all indications.

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation – Commercial and Individual Exchange Medical Policyopen_in_new

Policy CodePolicy 2026T0101NN

Change TypeClarifiedRevised (template and shared policy creation)

Effective DateJan 1, 2026

Next Review Date

Key ActionDocument medical records to demonstrate the member meets clinical criteria (e.g., prior AED trials, surgery candidacy/refusal, history of cervical vagotomy) because coverage is determined by member-specific benefit plans.

SourceLink

POLICY UPDATE CHANGES

Updated reference link to reflect current policy title for Transcranial Magnetic Stimulation for Treating Physical Health Conditions.

Created shared policy version to support application to Oxford plan membership.

1Covered Indication (epilepsy)

2Unproven: transcutaneous VNS and external TNS (all indications)

20Other unproven indications listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

3Conditions with limited supportive evidence (migraine, cluster headache, epilepsy)

7+Other conditions discussed (depression, ADHD, tinnitus, AF, heart failure, pain, sleep, glucose tolerance, PVCs)

FDADevices with FDA clearance/approval referenced

Coverage Summary

Scope: This policy defines UnitedHealthcare Commercial and Individual Exchange coverage rationale, clinical criteria, and coding references for vagus nerve stimulation (VNS) and external/transcutaneous trigeminal nerve stimulation (TNS). It applies to implantable and non-implantable VNS devices and external TNS devices and explicitly references applicable CPT/HCPCS/HCPCS supply and implantable device codes and FDA listings.

Coverage stance overview: Implantable VNS is covered/medically necessary for drug-resistant epilepsy when all specified clinical criteria are met (medically refractory seizures after ≥ two adequate antiepileptic trials, not a candidate/failed/refuses epilepsy surgery after shared decision making, and no history of left or bilateral cervical vagotomy). Implantable VNS is not covered/not medically necessary for indications beyond epilepsy due to insufficient evidence. Transcutaneous/non-implantable VNS (nVNS/tVNS) and external/transcutaneous TNS (eTNS) are considered unproven and not medically necessary for all indications because the evidence is insufficient to establish efficacy for the range of investigated conditions.

Key facts — Vagus & External Trigeminal Nerve Stimulation

Policy number2026T0101NN

Effective dateJanuary 1, 2026

SubjectVagus and External Trigeminal Nerve Stimulation

Document PartitionPolicy Part 3 of 3

Covered Indication (epilepsy)Implantable VNS medically necessary for drug‑resistant epilepsy when criteria met

Unproven therapies (transcutaneous/external)Transcutaneous (non‑implantable) VNS and external TNS are unproven/not medically necessary for all indications

Devices with FDA clearance/approval referencedFDA-approved/cleared implantable and non‑implantable VNS and eTNS devices (see FDA PMA/PMN listings)

Evidence ReferencesMultiple systematic reviews, RCTs, registries and guidelines cited (Cochrane, NICE, AAN, meta-analyses, pivotal trials)

Medical Necessity Criteria

Implantable Vagus Nerve Stimulators - Medically Necessary

Implantable vagus nerve stimulators are proven and medically necessary for treating epilepsy when ALL of the following criteria are met:

ALL of the following

Medically refractory epileptic seizures with failure of two or more trials of single or combination antiepileptic drug therapy or intolerable side effects of antiepileptic drug therapy
The individual is not a candidate for epilepsy surgery, has failed epilepsy surgery, or refuses epilepsy surgery after Shared Decision Making discussion
No history of left or bilateral cervical vagotomy (FDA contraindication)

Implantable Vagus Nerve Stimulators - Not Medically Necessary / Unproven

Implantable VNS is considered unproven and not medically necessary for treating other conditions due to insufficient evidence of efficacy, including but not limited to the following:

Evidence-based Conclusions for Indications

Evidence-based conclusions for indications

Coverage conclusions and evidence-based summaries for specific indications (each branch preserves the labeled conclusion, associated text, and notes):

ALL of the following

Cluster headache: nVNS may reduce frequency and intensity of cluster headache attacks and improve quality of life; treatment should continue only for people whose symptoms reduce in the first 3 months (NICE guidance).
Evidence supports adoption for cluster headache in some guidance but limits require monitoring
Migraine (preventive and acute): Evidence is insufficient or limited for many migraine indications; some trials show nVNS or eTNS can reduce migraine pain or responder rates in subsets (e.g., migraine with aura) but heterogeneity, small samples, sham device activity, and inconsistent results limit conclusions.
AHS recognizes FDA clearance for nVNS for acute migraine; NICE recommends use only with special arrangements for governance/consent/audit/research for acute treatment and research context for prevention.

Coding

Surgical / Procedural CPT Codes (reference)CPT

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.

Durable Medical Equipment / HCPCS / Supply Codes (reference)HCPCS

A4541	Monthly supplies for use of device coded at E0733.
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve.
E0735	Noninvasive vagus nerve stimulator.
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified.
E1399	Durable medical equipment, miscellaneous.

Implantable Neurostimulator Device Codes (reference)HCPCS

L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.

Regulatory device listings (informational)mixed

LYJ	PMA product code(s) for implantable VNS devices (see FDA PMA database)
MUZ	PMA product code (implantable VNS)
QPY	PMA product code (implantable VNS)
PKR	PMN product code (transcutaneous non-implantable VNS)
QAK	PMN product code (transcutaneous non-implantable VNS)
PCC	PMN product code (external/transcutaneous trigeminal nerve stimulation)
QGL	PMN product code (external/transcutaneous trigeminal nerve stimulation)

Provider Actions & Administrative Requirements

Documentation Required

Clinical documentation to support medical necessity

Medical records documentation may be required to verify that the member meets clinical criteria for coverage. Required documentation examples include prior trials of antiepileptic drugs (AEDs), documentation that the member is not a candidate for epilepsy surgery or has refused/failed surgery after shared decision making, and history of left or bilateral cervical vagotomy (contraindication). Coverage is determined by the member-specific benefit plan.

Prior AED trials (two or more single or combination trials)
Documentation of epilepsy surgery candidacy, failure, or documented refusal after Shared Decision Making
History of left or bilateral cervical vagotomy (FDA contraindication)
Coverage determination is member-specific and may require medical record review

Background & Definitions

Background and mechanisms: Implantable VNS delivers electrical impulses to the brain via the cervical vagus nerve using a surgically implanted pulse generator and leads; proposed mechanisms include neurotransmitter release modulation (norepinephrine, serotonin), increased thalamic and cortical blood flow, and EEG rhythm desynchronization. Closed-loop/responsive VNS variants detect physiologic signals (e.g., ictal heart-rate increases) to trigger stimulation.

Non‑implantable approaches: Transcutaneous VNS (tVNS / nVNS) delivers surface electrical stimulation to the auricular or cervical vagal branches (example device: gammaCore); external/transcutaneous trigeminal nerve stimulation (eTNS) applies stimulation to the supraorbital/infraorbital branches (example devices: Monarch eTNS system, Cefaly).

Evidence types and high-level summary: The evidence base comprises systematic reviews/meta-analyses, prospective registries, randomized controlled trials, and clinical guidelines. These support implantable VNS as an effective and tolerated adjunctive therapy for drug-resistant epilepsy (registry increases in responder rates, pooled responder rates in meta-analyses, and guideline recommendations from AAN and NICE). For other indications (depression, cluster headache, migraine, ADHD, heart failure, pain, tinnitus, stroke rehabilitation, and others) the literature is limited, heterogeneous, or of low quality (small trials, open-label designs, inconsistent sham controls), and therefore evidence is insufficient to conclude proven efficacy for implantable or non-implantable VNS/TNS in these conditions.

Term	Definition
Shared Decision Making
A collaborative process in which a provider/clinician and a patient (including caregivers and family) work together to make healthcare decisions considering evidence, provider experience, and patient values and preferences; comparing benefits, harms, and risks of options.
nVNS
Noninvasive vagus nerve stimulation (transcutaneous cervical or auricular devices).
eTNS / ETNS / TNS
External or transcutaneous trigeminal nerve stimulation (e.g., supraorbital stimulation/Cefaly device).

Evidence & References

Citation	Key finding
Diniz et al. (2024)
Replacement of tVNS by cardiac-based VNS associated with statistically significant ≥50% and ≥80% seizure reduction in meta-analysis of 7 studies.
Mao et al. (2021)
Pooled responder rates up to ~50% at longer follow-up; reported incidence of complications across multiple domains.
Englot et al. (2016) - Registry data
Progressive increase in responder rates over time; modest seizure freedom (≈5–8%).
Panebianco Cochrane (2015, updated 2022)
VNS appears effective and tolerated for partial seizures but evidence is moderate to low certainty (5 RCTs, 439 participants).
NICE (2022/2025)
Recommend considering VNS when resective surgery not viable and after shared decision making; special arrangements for non-implantable devices for migraine/cluster headaches.
PREMIUM trial (Diener 2019)
Preventive nVNS not superior to sham in ITT for episodic migraine; benefit seen in adherent subgroup (≥67% adherence).
Tassorelli (PRESTO, 2018)
nVNS superior to sham for pain freedom at 30 and 60 minutes for acute episodic migraine.
Song et al. (2023) meta-analysis
n-cVNS increased ≥50% responder rate (OR 1.64); n-aVNS reduced migraine days (MD -1.8) and intensity (SMD -0.7).
Gil-López et al. (2020)
ETNS randomized trial in focal DRE: 50% responders at 12 months vs 0% control; seizure frequency decreased by 43.5%.
ACT1/ACT2 meta-analysis (de Coo 2019 / Goadsby 2018)
nVNS superior to sham in episodic but not chronic cluster headache (acute treatment endpoints).
Najib et al. (PREMIUM II, 2022)
In adherent modified ITT subgroup, responder rates favored active nVNS; primary endpoint underpowered due to COVID-19 impact.

Revision History

02/01/2026Summary of ChangesLatest

Updated reference link to reflect the current policy title for Transcranial Magnetic Stimulation for Treating Physical Health Conditions; related policies updated per revision history (non-material).

01/01/2026Template update and shared policy version

Created shared policy version to support application to Oxford plan membership; archived previous policy versions 2025T0101MM and SURGERY 073.30 (template/revision, non-material).

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation – Commercial and Individual Exchange Medical Policyopen_in_new

Policy CodePolicy 2026T0101NN

Change TypeClarifiedRevised (template and shared policy creation)

Effective DateJan 1, 2026

Next Review Date

SourceLink

On This Page

ANY of the following

Alzheimer's disease
Anxiety disorder
Autism spectrum disorder
Autoimmune disorders
Back and neck pain
Bipolar disorder
Bulimia
Cerebral palsy
Chronic pain syndrome
Cluster headaches
Depression
Fibromyalgia
Heart failure
Migraines
Morbid obesity
Musculoskeletal disorders
Narcolepsy
Obsessive-compulsive disorder
Paralysis agitans
Sleep disorders
Tourette's syndrome
Upper limb impairment related to stroke

Transcutaneous (Non-Implantable) VNS and External TNS - Not Medically Necessary / Unproven

The following non‑implantable/transcutaneous stimulation therapies and external devices are unproven and not medically necessary for preventing or treating any indications:

ALL of the following

Transcutaneous (non-implantable) vagus nerve stimulation devices for preventing or treating all indications
External or transcutaneous (non-implantable) trigeminal nerve stimulation devices for preventing or treating all conditions including but not limited to ADHD, depression, epilepsy, headache

Chronic migraine: Studies (pilot and small RCTs) show mixed results; preventive nVNS was not superior to sham in some ITT analyses but showed benefit in adherent subgroups; evidence considered insufficient to broadly support coverage.

Adherence and sham stimulation confound results

Drug-resistant epilepsy and focal epilepsy: Some small RCTs and systematic reviews suggest ETNS/TNS may reduce seizure frequency in focal or drug-resistant epilepsy, with responder rates reported in small trials, but overall evidence is limited and inconsistent; further larger trials needed.

Insufficient data to conclude proven efficacy

ADHD in children: One sham-controlled trial (TNS) showed improvement in ADHD symptoms but AAP guideline states eTNS cannot be recommended due to sparse evidence compared with established treatments.

Not recommended by AAP

Depression and other conditions: Evidence for VNS/t-VNS/eTNS in depression, tinnitus, atrial fibrillation, heart failure, pain, premature ventricular contractions, sleep, schizophrenia, impaired glucose tolerance and other conditions is limited, with insufficient data to conclude safety/effectiveness.

Further trials needed

Evidence summary: The evidence base cited includes systematic reviews and meta-analyses (e.g., Diniz 2024, Mao 2021, Panebianco Cochrane 2015/2022, Song 2023), prospective registries (e.g., Kawai national registry, Englot VNS Outcome Registry), randomized controlled trials and multicenter device trials (e.g., PREVA, ACT1/ACT2, PREMIUM, PRESTO, Tassorelli 2018, Gil-López 2020), and guideline statements (NICE, AAN, AHS, AAP).

Overall quality and limitations: For implantable VNS in drug-resistant epilepsy the evidence includes registry data and meta-analyses showing increasing responder rates over time but randomized trial evidence is limited in size; Cochrane judged certainty as moderate-to-low due to few trials and incomplete reporting. For non-implantable nVNS and eTNS the literature contains small RCTs, heterogeneous stimulation parameters, varying sham devices, adherence issues and inconsistent results; some trials show benefit in subgroups (e.g., episodic cluster headache, adherent migraine patients, focal DRE in one ETNS trial) but overall quality is limited. Guideline positions (NICE, AAN, AHS, AAP) reflect cautious endorsement for implantable VNS in selected epilepsy patients and recommend special arrangements, limited use, or further research for non-implantable therapies.

Billing Rule

Codes are reference-only and do not guarantee coverage

The list of procedure, supply, and device codes in this policy is provided for reference only. Inclusion of a code does not imply coverage, reimbursement, or guarantee of claim payment; other policies and the member-specific benefit plan govern.

CPT: 61885, 61886, 64553, 64568, 64570
HCPCS/DME: A4541, E0733, E0735, E0770, E1399
HCPCS device codes: L8679, L8680, L8682, L8683, L8685, L8686, L8687, L8688

Documentation Required

Use with governance/consent/audit or research (per NICE)

For transcutaneous cervical vagus stimulation and supraorbital external trigeminal nerve stimulation, NICE recommends use only with special arrangements for clinical governance, informed consent, and audit or in research contexts. Providers should document the governance/consent arrangements and outcome monitoring when using these non-implantable devices.

Document clinical governance arrangements and consent
Track and audit outcomes or use within research protocols
Apply special arrangements per NICE guidance for nVNS and supraorbital stimulation

Documentation Required

Adherence monitoring

Therapeutic benefit in some trials was confined to adherent patients; for example, a subgroup with ≥ 67% adherence showed benefit in the PREMIUM trial. Document device adherence when assessing clinical response.

Example adherence threshold: ≥ 67% (used in PREMIUM analyses)
Document adherence when assessing response to therapy

Documentation Required

Trial duration for cluster headache

When treating cluster headache with noninvasive VNS, continue therapy only for people whose symptoms reduce in the first 3 months; document clinical response within that 3-month trial period per NICE guidance.

Document response within 3 months and continue treatment only for responders

Documentation Required

Reference member-specific benefit plan

Always reference the member-specific benefit plan document when determining coverage because plan terms may differ from this standard policy; in a conflict, the member-specific benefit plan governs.

Check the member-specific benefit plan language before approving services
Member-specific plan governs in the event of conflict with this policy

Documentation Required

Check Medicare guidance for Medicare Advantage

Before applying this policy to Medicare Advantage members, verify applicable Medicare coverage guidance (NCDs/LCDs). In the absence of an NCD or LCD, a Medicare Advantage Organization may develop its own coverage determinations using objective evidence-based rationale.

Check for applicable Medicare NCDs or LCDs
If none exist, confirm MAO-specific coverage determinations prior to application

Billing Rule

Policy application to Oxford plan membership

A shared policy version was created to support application to Oxford plan membership effective 01/01/2026; prior policy versions have been archived per the revision history.

Shared policy version date: 01/01/2026
Previous versions archived (see policy history)